PASIREOTIDE

Summary

Pasireotide is a multi-receptor somatostatin receptor ligand approved as a prescription therapy, with a monthly long-acting intramuscular formulation approved for both acromegaly and Cushing's disease ^[1]. In acromegaly it serves as an adjuvant option after surgery, with ongoing efforts to identify biomarkers and an acute test to predict responders ^[2,3], and in Cushing's disease it provides biochemical control and additionally reduces tumor volume, having been evaluated in high-quality studies ^[4]. Its efficacy has been demonstrated from preclinical work through phase III clinical trials ^[3]. The most clinically important safety signal is hyperglycemia, driven by modest suppression of the incretin effect, while cardiac valve disease and psychiatric effects also warrant attention; overall the drug is regarded as well tolerated ^[1,3,4]. The human evidence is strong and supports pasireotide as an established approved therapeutic.

Sources

1. 1. Pasireotide-a novel somatostatin receptor ligand after 20 years of use Reviews in endocrine & metabolic disorders, 2022.
2. 2. Pasireotide in the Personalized Treatment of Acromegaly Frontiers in endocrinology, 2021.
3. 3. Pasireotide for the treatment of acromegaly Expert opinion on pharmacotherapy, 2016.
4. 4. Pituitary acting drugs: cabergoline and pasireotide Pituitary, 2022.

For educational purposes only.